Virios Therapeutics Inc. Common Stock
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
VIRI Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$2.1400 |
Previous Close Volume |
745920 |
Latest News
-
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
18 Nov 2024 09:07:20
https://ir.dwtx.com/news/press-releases/detail/127/dogwood-therapeutics-inc-announces-low-dose-imc-2
- Dogwood Therapeutics Announces Third Quarter 2024 Financial Results 07 Nov 2024 07:20:15
- Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 31 Oct 2024 09:20:26
- Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement 30 Oct 2024 09:35:28
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) 07 Oct 2024 07:08:11
- Virios Therapeutics Announces Second Quarter 2024 Financial Results 08 Aug 2024 09:38:59
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 01 Aug 2024 09:54:24
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center 23 Jul 2024 09:24:20
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study 22 May 2024 13:54:37
- Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study 17 May 2024 16:24:30
- Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update 09 May 2024 07:54:41
- Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 02 May 2024 09:24:47
- Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID 26 Mar 2024 09:25:18
- Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results 29 Feb 2024 09:40:42
-
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
28 Feb 2024 09:40:46
https://ir.virios.com/news/press-releases/detail/112/virios-therapeutics-issues-shareholder-letter
-
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
22 Jan 2024 09:11:04
https://ir.virios.com/news/press-releases/detail/111/virios-therapeutics-announces-plans-to-advance